This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Reed SD, Anstrom KJ, Li Y, Schulman KA.Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. PharmacoEconomics 26: 435-446, No. 5, 2008
Rights and permissions
About this article
Cite this article
Imatinib still cost effective for CML. Pharmacoecon. Outcomes News 553, 9 (2008). https://doi.org/10.2165/00151234-200805530-00015
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805530-00015